Blog

Jun 02, 2023

Mycophenolic acid directly protects podocytes by preserving the actin cytoskeleton and increasing cell survival

Scientific Reports volume 13, Article number: 4281 (2023) Cite this article 749 Accesses 1 Altmetric Metrics details Mycophenolate Mofetil (MMF) has an established role as a therapeutic agent in

Scientific Reports volume 13, Article number: 4281 (2023) Cite this article

749 Accesses

1 Altmetric

Metrics details

Mycophenolate Mofetil (MMF) has an established role as a therapeutic agent in childhood nephrotic syndrome. While other immunosuppressants have been shown to positively affect podocytes, direct effects of MMF on podocytes remain largely unknown. The present study examines the effects of MMF’s active component Mycophenolic Acid (MPA) on the transcriptome of podocytes and investigates its biological significance. We performed transcriptomics in cultured murine podocytes exposed to MPA to generate hypotheses on podocyte-specific effects of MPA. Accordingly, we further analyzed biological MPA effects on actin cytoskeleton morphology after treatment with bovine serum albumin (BSA) by immunofluorescence staining, as well as on cell survival following exposure to TNF-α and cycloheximide by neutral red assay. MPA treatment significantly (adjusted p < 0.05) affected expression of 351 genes in podocytes. Gene Ontology term enrichment analysis particularly clustered terms related to actin and inflammation-related cell death. Indeed, quantification of the actin cytoskeleton of BSA treated podocytes revealed a significant increase of thickness and number of actin filaments after treatment with MPA. Further, MPA significantly reduced TNFα and cycloheximide induced cell death. MPA has a substantial effect on the transcriptome of podocytes in vitro, particularly including functional clusters related to non-immune cell dependent mechanisms. This may provide a molecular basis for direct beneficial effects of MPA on the structural integrity and survival of podocytes under pro-inflammatory conditions.

Mycophenolic acid (MPA) is the active component of the prodrug mycophenolate mofetil (MMF). MPA acts as a highly selective and potent inhibitor of the inosine-5′-monophosphate dehydrogenase (IMPDH), leading to a depletion of the pool of guanosine triphosphate (GTP) and deoxy GTP1,2. It has been shown that MPA binds the type II isoform of IMPDH, expressed in activated B- and T-lymphocytes, with an affinity five times higher than the constitutively expressed type I isoform, leading to an effective blockage of lymphocyte proliferation while having only minor effects on the multiplication of other cell types3,4. This mechanism of action, which results in a comparably low adverse risk profile, has led to a wide use of MMF in the field of organ transplantation, where it emerged as an effective drug for prevention of acute rejection of, inter alia, kidney allografts5. Further, MMF has been a vital part of systemic lupus erythematosus therapy, especially in patients with solid organ manifestations, such as lupus nephritis6. MMF is also recommended as a glucocorticoid sparing agent for steroid sensitive nephrotic syndrome in the recently published KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases7. Its use in treating the most prevalent cause of glomerular disease in children, the idiopathic nephrotic syndrome (INS), has been constantly expanding8. Despite extensive research the pathomechanism of INS has not yet been fully elucidated. Traditionally, INS has been viewed as a T-lymphocyte derived disease, but successful treatment with the anti-CD20 antibody rituximab has amended this viewpoint9,10,11,12. Importantly, there has been increasing evidence for a central role of podocytes in the pathogenesis of INS. Podocytes are terminally differentiated cells, whose foot processes (FP), interdigitate with those of neighboring podocytes. This connection constitutes the outer layer of the glomerular filtration barrier, the slit diaphragm (SD)13. During disease the actin cytoskeleton undergoes dynamic changes, thereby inducing FP effacement, which leads to a reduced compressive force on the glomerular membrane and consequently, to the loss of albumin and other proteins into the urine14,15,16. Other immunosuppressants used in treating INS such as glucocorticoids, cyclosporine A and rituximab positively affect the actin cytoskeleton of podocytes as part of their antiproteinuric effect17,18,19. Research into the effect of MPA on kidney cells is scarce. In both in vitro and in vivo experiments, it has been shown that MPA inhibits the proliferation of mesangial cells, through the depletion of the guanosine pool20,21. With regard to podocytes, MPA showed a preservative effect on nephrin expression in adriamycin-induced nephritis and diabetes mellitus models22,23. In the latter model, MPA was able to reduce podocyte apoptosis through a reduction of Bax and cleaved caspase-3 (CC3) protein levels. Transcriptomic analysis of murine kidneys in a lupus nephritis model showed an increase in actin associated terms after treatment with MMF24. In the same study, MMF reduced the activation of Rac1 of cultured podocytes compared to controls. To improve our insight into the effect of MPA on podocytes, we were prompted to further investigate direct, non-immune cell mediated responses through which MPA could favorably affect these cells. We therefore performed a transcriptomic analysis of MPA treated podocytes, followed by an investigation of the functional impact of the discovered changes in mRNA levels.

A conditionally immortalized murine podocyte cell line (kindly provided by Dr. P. Mundel) was cultivated on type I collagen (A1064401—Invitrogen) coated culture dishes and kept in RPMI-1640 Medium + GlutaMAX (#61870036, Gibco), supplemented with 10% fetal bovine serum (FBS, 10270106—Gibco), 1% HEPES solution (H0887—Sigma) and 1% sodium pyruvate (S8636—Sigma) at 33 °C in the presence of recombinant mouse Interferon-\(\gamma\)(INF-\(\gamma\), #315–05, PeproTech) to allow proliferation at permissive conditions. This was followed by incubation at 37 °C without additional INF-\(\gamma\) for 10 days to induce differentiation at the non-permissive condition, as described previously25. Differentiation was confirmed by synaptopodin staining (data not shown). Cells were regularly checked for Mycoplasma infection. After differentiation, cells were treated with MPA (M3536—Sigma-Aldrich) with a concentration of 10 mg/L for 2 h, followed by a concentration of 4 mg/L for 22 h. MPA concentrations were chosen based on the pharmacokinetics of MPA plasma concentrations measured in children with idiopathic nephrotic syndrome26. Cells of the control group received the respective amount of methanol as vehicle (Fig. 1A).

Treatment with MPA leads to changes in the transcriptome of podocytes. (A) Conditionally immortalized podocytes were differentiated treated with either Vehicle or Mycophenolic Acid (MPA) for 24 h and subjected to RNAseq analysis. (B) Volcano Plot visualizing the effects of MPA on the transcriptome of podocytes. Blue, adjusted p-value (padj) < 0.05; red, padj > 0.05. MPA treatment resulted in 130 significantly downregulated and 221 significantly upregulated genes. (C) Genes were sorted into a heatmap according to their z-score transformation value, resulting in four clusters. Cluster 1, red, downregulated genes. Cluster 2, blue, highly downregulated genes. Cluster 3, green, upregulated genes. Cluster 4, orange, highly upregulated genes. (B) Clusters were subjected to a Gene Ontology (GO)-term enrichment analysis. Important significantly enriched terms are summarized for each cluster.

Cells were treated according to treatment protocol A (Fig. 1A). Total RNA was extracted using an RNA-Extraction Kit by Zymo Research (R2052direct-zol RNA-miniprep) according to the manufacturers’ instruction, mRNA sequencing was performed at the Cologne Center for Genomics. Libraries were prepared using the Illumina® Stranded TruSeq® RNA sample preparation Kit. Library preparation started with 2 µg total RNA. After poly-A selection (using poly-T oligo-attached magnetic beads), mRNA was purified and fragmented using divalent cations under elevated temperature. The RNA fragments underwent reverse transcription using random primers. This was followed by second strand cDNA synthesis with DNA Polymerase I and RNase H. After end repair and A-tailing, indexing adapters were ligated. The products were then purified and amplified (14 PCR cycles) to create the final cDNA libraries. After library validation and quantification (Agilent Tape Station), equimolar amounts of library were pooled. The pool was quantified by using the Peqlab KAPA Library Quantification Kit and the Applied Biosystems 7900HT Sequence Detection System. The pool was sequenced on an Illumina NovaSeq6000 sequencing instrument with a PE100 protocol27,28.

The reads were trimmed with Trimmomatic (version 0.36) using default parameters29. Additionally, up to ten low quality bases in the beginning of the reads were removed. The trimmed reads were mapped to the GRCm39 mouse reference genome with STAR version 2.6.0 using default parameters30. The analysis of differential gene expression was performed using the R package DeSeq2 (version 1.26.0)31,32. For visualization purposes the batch effect was removed using the method removeBatchEffect from the R package limma33. The enrichment analysis was done using the R package topGO34,35. For the heatmap and clustering the R package pheatmap was used36. The Z-transformed gene expression of genes with an adjusted p-value (padj) < 0.05 (calculated by DeSeq2) in the comparison MPA vs control was visualized and clustered in the heatmap.

Undifferentiated podocytes were seeded on coverslips and differentiated as described above. After differentiation, cells were incubated in medium with fatty-acid free, low endotoxin bovine serum albumin (BSA, A8806 –Sigma-Aldrich) at a concentration of 50 mg/ml for 48 h (BSA + vehicle [veh]). We used the study design of Yoshida et al.37 as orientation but adjusted the concentration of BSA to reach a robust injury model, where Type C and Type D cells prevail. The treatment group received additional MPA treatment in the second half of the 48 h (BSA + MPA). An additional group was treated only with MPA (MPA). Cells without BSA exposition and MPA treatment served as controls (Fig. 2A). The treated cells were then fixed with 4% paraformaldehyde prior to blocking and permeabilization with 5% Normal Donkey Serum and 0.1% Triton X-100 in phosphate buffered saline solution (PBS) for 30 min. Cells stained for synaptopodin were incubated with a synaptopodin antibody (S9442—Sigma-Aldrich, 1:500) overnight, followed by incubation with the appropriate secondary antibody at room temperature (RT) for 60 min (Alexa Fluor® 488 AffiniPure Donkey Anti-Rabbit IgG (H + L), 1:250). Cells stained for actin were incubated with fluorescently conjugated phalloidin at RT for 60 min (647P1-33—Dyomics, 1:50). The coverslips were then mounted with Prolong Gold and DAPI. Images were acquired with a Zeiss Meta 710 Confocal Laser Scanning Microscope and processed with ImageJ. For quantitative analysis of actin fiber assembly patterns, a previously described scoring system was adapted, and images were scored by an observer blinded to cell treatment38. At least 90 cells were analyzed per sample. The four groups describing the different actin fiber assembly patterns were defined as follows: Type A: 90% of cell area filled with thick cables; type B: at least two thick cables running under the nucleus, the rest of the cell area filled with fine cables; type C: no thick cables but some cables present; and type D: no cables visible in the central area of the cell (Fig. 2B).

MPA protects the actin cytoskeleton from BSA induced injury. (A) Cells were treated with bovine serum albumin (BSA) for 48 h and received either MPA or Vehicle for the second 24 h. The actin cytoskeleton was visualized using immunofluorescence staining. (B) Quantification of different cell types after treatment with bovine serum albumin (BSA) and Mycophenolic Acid (MPA). Grey = Type A: > 90% of cell area filled with thick cables; green = type B: at least two thick cables running under the nucleus, with the rest of the cell area filled with fine cables; yellow = type C: no thick cables but some cables present; red = type D: no cables visible in the central area of the cell. BSA treatment decreases healthy Type A and B cells, while increasing less healthy Type C and D cells. Additional MPA treatment reverses this effect in all categories, increasing Type A and B cells compared to BSA only, while decreasing Type C and D cells. The treatment with only MPA resulted in a similar distribution of cell types as in controls. At least 90 cells were analyzed per sample. (C) Quantification of Type D cells for each treatment. Treatment with BSA significantly increases the number of cableless D cells. In contrast additional treatment with MPA significantly decreases the number of D cells compared to treatment with only BSA **p < 0.01. (D) Representative confocal images of the podocytes after each respective treatment. Green, phalloidin. Blue, DAPI.

Cells were seeded and differentiated in a 96-well culture dish. After differentiation, the treatment group was pretreated with MPA for 24 h. Afterwards cells were treated with recombinant mouse Tumor Necrosis Factor-α (TNF-α; Recombinant Mouse TNF-alpha [aa 80–235] Protein, #410-MT, R&D Systems, 20 ng/ml), Cycloheximide (CHX; C4859, Sigma-Aldrich, 5 µg/ml) and MPA for an additional 24 h (TCM). We used TNF-α in combination with the synergistically acting CHX in order to reach a high susceptibility to apoptosis39,40. Other treatment groups included cells receiving only TNF-α and CHX (TC), as well as cells receiving TNF-α, CHX and a pan-caspase inhibitor, Emricasan (SEL-S7775, Biozol) (TCE)41. Cells receiving only the vehicles of all respective agents served as control. An additional control group received only MPA for 48 h (M). The treatment schedules and concentrations of all agents are visualized in Fig. 3A. During the last 2 h of treatment, neutral red was added to each well. Next, cells were washed, and the dye was extracted out of viable cells with a destaining solution (50% EtOH, 49% VE H2O, 1% acetic acid). The absorbance of each well was measured through a spectrophotometer at 540 nm. The amount of viable cells was calculated as a ratio of the absorbance of each well to the absorbance of their respective control. Each condition was conducted with triplets of three different passages.

MPA increases cell viability during TNF-α and CHX induced cell death. (A) Cells were treated with either Vehicle or MPA (M) for 48 h, or Emricasan (E) for 24 h. All cells received Tumor Necrosis Factor-α (T) and Cycloheximide (C) for 24 h. An additional control group received only MPA for 48 h (M). This resulted in 5 treatment groups (Control, TC, TCM, TCE and M), which were analyzed with a cell viability assay. (B) Quantification of cell viability after treatment with combinations of Tumor Necrosis Factor-α (TNF-α; T), Cycloheximide (CHX; C), Mycophenolic Acid (MPA; M) and Emricasan (E). Control cells received only vehicles. Cell viability of each sample was normalized against the control of their respective passage. TC-treatment resulted in a drastic decrease of cell viability. Additional MPA treatment significantly increases cell viability compared to TC only (36.8 vs. 62.9%). Emricasan was able to prevent cell death in a very high degree (91%). Treatment with only MPA showed no signs for proliferative activity of the drug. **p < 0.01 (C) Western Blot Analysis of cleaved Caspase-3 levels. Lane 1, Control. Lane 2, TC. Lane 3, TCM. Treatment with TC results in a steep increase of cleaved Caspase-3 levels. TCM treated cells display a reduction of cleaved Caspase-3 compared to TC treated cells. Fl, full length. DMSO, Dimethyl sulfoxide. MtOH, Methanol. Gapdh, Glyceraldehyde 3-phosphate dehydrogenase. The displayed blot was cropped for better visualization. The boxes exemplify different regions of the same gel. The uncropped blots can be found as Supplementary Fig. 1.

Cells of the treatment groups Control, TC and TCM were treated as described above (Fig. 3A). Treated cells were scraped off the dishes with ice cold PBS and cell pellets were isolated through centrifugation at 5.000 rpm for 5 min, before being snap frozen in liquid nitrogen. The cell pellets were resuspended in RIPA Buffer with additional Na3VO4 (20 µl/ml) and phenylmethylsulfonylfluoride (4,4 µl/ml) and then subject to the BCA Method to determine the amount of total protein. 15 µg of total protein were loaded per lane on 10% or 12% SDS-Page gels. The separated proteins were transferred onto polyvinylidene difluoride membranes, which were blocked in 5% BSA for 1 h. Next, the membranes were probed with primary antibodies overnight at 4 °C. After washing, the membranes were incubated with the secondary antibody at RT for 1 h. The signals were visualized with SuperSignal West Femto Maximum Sensitivity Substrate (#34095, Thermo Scientific) and bands were quantified using Fiji-ImageJ Version 2.1.0/1.53c42. Protein expression was quantified as the ratio of a specific band to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

The following primary antibodies were used in this study: cleaved Caspase-3 (Asp175) Antibody #9661 (Cell Signaling Technology), 1:1.000; GAPDH (D16H11) XP® Rabbit mAb#5174 (Cell Signaling Technology), 1:1.000. A horseradish peroxidase-conjugated goat antibody against rabbit (Cy™3 AffiniPure Donkey Anti-Rabbit IgG (H + L), AB_2307443, Jackson Immuno Research) was used as a secondary antibody (1:30.000).

A two-way ANOVA test was used to compare the quantification of the actin cytoskeleton. A t-test with Welch’s correction was used to compare the results of the cell viability assay. Results with p < 0.05 were considered statistically significant. Results are reported as mean \(\pm\) SEM.

To gain a profound overview about the MPA-induced processes, we conducted an RNA sequencing (RNAseq) of MPA-treated podocytes. The experimental design is shown in Fig. 1A. We identified 351 genes that met the criterion of an adjusted p < 0.05 in order to be considered significantly affected by MPA treatment compared to controls.

A volcano plot visualizes the distribution of gene transcripts, showing that of the 351 differentially expressed genes 130 were significantly reduced and 221 were significantly increased (Fig. 1B). Both isoforms of IMPDH were highly expressed in all samples, with a consistently higher read count for IMPDH II (Suppl. Data). Interestingly, IMPDH II showed a significant, compensatory upregulation upon MPA treatment (log2FC 0.26, padj = 0.0002).

In order to better reveal inherent relations between these genes, we organized our data by the z-score transformed gene expression of each gene (Fig. 1C). Comparison of the data demonstrates a considerable consistency of expression changes inside each condition. Four gene meta-clusters were identified: down-regulated (Cluster 1), highly down-regulated (Cluster 2), up-regulated (Cluster 3) and highly up-regulated (Cluster 4).

To clarify molecular functions and biological processes affected by MPA-regulated genes and to address their relevance in podocytes, we next performed enrichment analysis for each cluster using Gene Ontology (GO). Figure 1C also depicts a selection of significant terms associated with each cluster. Complete result tables of enrichment are provided as supplementary information (Supplementary Dataset File 1–4). Looking at the results of the enrichment analysis we could outline two major groups of terms that were of particular interest.

Looking at the significant terms of the clusters with genes induced upon MPA treatment (cluster 3 and cluster 4), we noticed an accumulation of terms related to the cytoskeletal structure of the cell. On the one hand, we had an increase of terms narrowing down the cellular components affected by the differentially expressed genes, like actin cytoskeleton (fold enrichment [FE] 1.7, p = 0.01), stress fiber (FE 2.2, p = 0.03), or actomyosin (FE 2.0, p = 0.04) (Fig. 1C). On the other hand, we could also see an increase in terms associated with the dynamic changes of those cellular components, like actin filament bundle assembly (FE 2.5, p = 0.01) and regulation of Rho protein- and small GTPase mediated signal transduction (FE 3.2 and 3.0, p = 0.004 and 0.03 respectively). Genes annotated to the terms of this subgroup include SYNPO2L (log2FC 0.80, padj = 466E-10), an actin associated protein from the synaptopodin family, and ITGB1 (log2FC 0.17, padj = 0.0006), a protein crucial for cytoskeletal organization and signal transduction in podocytes. Further, we could see an upregulation of guanine nucleotide exchange factors (e.g., ARHGEF2), downstream effectors of RhoA (e.g., ROCK2) and other proteins that influence the activity of smallGTPases (e.g., AMOT) (Table 1).

Another major group that came to our attention includes terms related to inflammatory pathways and cell death. Here, we could see an increase in terms describing the downregulation of inflammatory pathways, especially the p38-Mitogen activated protein kinase (p38MAPK) and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. The negative regulation of p38MAPK cascade (FE 5.3, p = 0.001) presented itself as the GO-term with the largest fold enrichment (Fig. 1C). Notably, we found an increase in gene transcripts of the dual specificity protein phosphatase (DUSP) family, namely DUSP1, DUSP4 and DUSP6 (log2FC 0.23, 0.39, 0,31 and padj = 0.0004, 9.33E-05, 0.007 respectively). Treatment with MPA also increases the transcription of ubiquitin carboxyl-terminal hydrolase CYLD (log2FC 0.12, padj = 0.04), which is known to suppress the NF-κB, p38MAPK and c-Jun N-terminal kinase (JNK) cascades. Simultaneously, terms concerning the activation of these pathways through INF-χ and transforming growth factor-β (TGF-β) were significantly downregulated and therefore appeared in Cluster 1. One example of a downregulated transcript is THBS1 (log2FC − 0.16, padj = 0.006), which, if translated, can lead to an activation of TNF-α and TGF-β pathways. The transcript with the largest negative fold change after MPA treatment is PLK-1 (log2FC − 1.03, padj = 0.0004), which translates into a serine-threonine kinase with important functions in cell cycle regulation. In addition to the regulation of terms concerning inflammatory pathways, we could also see a surge of terms mentioning the negative regulation of cell death pathways, such as apoptosis and necroptosis. Mentionable examples of genes regulated by MPA and annotated to these functions are CCN-I, PEA15A, and DDX3X (Table 2).

To validate the biological significance of changes in the actin cytoskeleton related genes, we designed an experimental setup intended to damage actin filaments in a non-immunological manner and with resemblance to the pathophysiology of the nephrotic syndrome (Fig. 2A). We then stained the cells with Phalloidin, which interacts highly selectively with F-actin, to visualize the cytoskeletal structure of each cell (Fig. 2D). After 48 h of incubation with BSA, cells showed a disorganization of the actin cytoskeleton and an increased appearance of vacuoles. The quantification of the cytoskeleton revealed a substantial decrease of cells with thick cables (Type A and B) after treatment with BSA compared to controls. Simultaneously, the number of cells with thin or no cables (Type C and D) increased remarkably compared to control cells (Fig. 2B). Interestingly, the BSA + MPA group displayed a vastly different appearance, compared to the BSA + veh group. The number of Type A and B cells increased significantly compared to cells treated only with BSA (p = 0.004 and p = 0.001 respectively, Fig. 2B). Concomitantly, the share of non-stress fiber containing Type D cells decreased in a significant manner (p = 0.004, Fig. 2C), displaying an approximation of the actin cytoskeleton pattern of BSA + MPA cells, to that of control cells. The treatment with only MPA resulted in a similar distribution of cell types as in controls.

Next, we examined consequences of the transcriptomic changes regarding inflammation and cell death in a functional environment. In view of the pathways that appear to be affected by MPA treatment, we chose TNF-α and CHX as appropriate, synergistically acting stressing agents, with a potent ability to induce cell death. The experimental design is shown in Fig. 3A. Using the neutral red uptake assay, we discovered that treatment with TNF-α and CHX reduced cell viability to only 36.8% (Fig. 3B). If simultaneously treated with MPA, no significant difference in cell survival was notable (data not shown). In contrast, cells with a treatment schedule including 24 h of pretreatment with MPA, showed a significantly reduced cell death rate, with 62.9% of cells viable after incubation with TNF-α and CHX (Fig. 3B, p = 0.008). Emricasan, an inhibitor of pan-caspases, was able to strongly diminish the cell damaging activity of the two agents, leaving 91% of cells viable after treatment. A proliferative effect due to MPA treatment was ruled out using an MPA-only group (Fig. 3B). To further validate our results and to elucidate the role of caspase-inhibition through MPA, we decided to perform a Western Blot analysis of CC3 levels. As expected, TC treatment strongly initiated Caspase-3 cleavage. More importantly, we found that additional MPA treatment decreased the amount of CC3 (Fig. 3C). A quantification of the western blot results can be found in the supplementary information (Supp. Fig. 2).

To our knowledge, we are the first to use an unbiased transcriptomic approach in order to investigate how MPA affects podocytes in a non-immunologic environment in a favorable manner. Interestingly, the result of the transcriptomic analysis showed that treatment with MPA for 24 h increased gene transcription of IMPDH II significantly (Fig. 1B), implying an effective exposure to MPA. This result is in line with past research, which had also demonstrated that murine podocytes express IMPDH transcripts and that IMPDH activity can be inhibited in cell culture43.

Hierarchical clustering identified 4 clusters, which were then analyzed for functional implications by conducting a GO-Term Enrichment Analysis. Upon closer examination we discovered that there was an accumulation of enriched terms associated to actin, especially in clusters of upregulated genes, such as actin cytoskeleton and regulation of small GTPase mediated signal transduction (Fig. 1C). Actin is the predominant cytoskeletal structure in FPs and as reviewed previously its reorganization or dysfunction can be a leading cause for proteinuria44,45,46. Since stabilization of the actin cytoskeleton has been demonstrated as a direct effect of cyclosporine A on podocytes19 we tested if MPA has a similar ability to directly act on the podocyte actin cytoskeleton. Therefore, we designed an experimental setup in which BSA was used as a stressing agent. In line with previous literature37, BSA treatment markedly decreased the amount and thickness of stress fibers. Notably, MPA was able to protect the cells from the albumin overload induced injury. Treatment with MPA reconstituted the number of actin rich Type A and B cells, while showing a significant decrease of Type D cells compared to the BSA + veh group (Fig. 2B,C).

This result strongly supported our concept of a stabilizing effect of MPA on the actin cytoskeleton. Next, we went back to our transcriptome data and looked at the actin cytoskeleton stabilization associated genes in more detail. The first interesting candidate was SYNPO2L (Table 1). SYNPO2L is a member of the synaptopodin family, which has been shown to stabilize the actin cytoskeleton in numerous studies38,47,48,49. If overexpressed SYNPO2L itself can activate the actin signaling pathway, increasing proteins like RhoA and Actn2 while inducing stress fiber formation50. Since synaptopodin is lost in childhood nephrotic syndrome51, an increase in a member of the synaptopodin family, like SYNPO2L, could potentially compensate for the loss of the actin supporting protein. Another interesting gene regulated through MPA is ITGB1, a major adhesion molecule in podocytes, which is downregulated under mechanical stress as well as under albumin overload, both being leading pathological mechanisms in INS52,53. The decrease of ITGB1 can result in a reduced podocyte adhesion and an increase in Caspase-3 activity54. Lee et al. were able to show that pyrintegrin, a beta1-integrin-agonist, is able to protect murine podocytes from effacement and subsequently mice from proteinuria55. In our study we discovered that MPA increases ITGB1 gene transcription, thereby possibly making use of its stabilizing effect on podocytes.

Further examination of the RNAseq-data revealed another group of terms, including negative regulation of p38MAPK and negative regulation of apoptotic process in the upregulated clusters and a negative regulation of TGF-β receptor signaling pathway, that are linked to cell death and inflammation (Fig. 1C). The p38MAPK-pathway is a well-known pro-inflammatory and pro-apoptotic pathway, that is among other things activated during endoplasmic reticulum stress (ERS)56,57. ERS, TGF-β and p38MAPK have all been shown to be upregulated through albumin overload in podocytes in vitro37,58. Koshikawa et al. were able to demonstrate that p38MAPK-activation is increased in rodent kidney disease models, as well as in human glomerulopathies, including MCGN and FSGS59. In line with these findings, the inhibition of TGF-β and p38MAPK proved to be protective for podocytes in vitro and in vivo37,59,60. Considering our transcriptomic analysis together with the aforementioned studies, we tested if MPA has the ability to protect podocytes from inflammation and subsequent cell death and examined this hypothesis using a cell viability assay. Previous work had shown that nephrotic syndrome in mice and albumin exposure to podocytes in vitro increase TNF-RNA61, which in turn can induce podocyte injury and glomerular disease progression62,63. We therefore treated our cells with a routinely used combination of TNF-α and CHX, which showed a massively detrimental impact on podocyte survival. Nonetheless we were able to demonstrate a significantly higher survival of cells pre-treated with MPA compared to those not treated with MPA (62.9% vs. 36.8%, Fig. 3B). Thus, our data impressively demonstrate that TNF-α -induced cell death can effectively be mitigated when cells are pretreated with MPA. On the contrary, treatment with MPA after stimulation with TNF-α was not successful in preventing cell death. Subsequently, we demonstrated that MPA treatment reduces Caspase-3 cleavage induced by TC treatment (Fig. 3C). Taken together, we were able to show that MPA attenuates TNF-α induced cell death in cultured podocytes. Mechanistically, this can at least partially be related to a reduction of Caspase-3 activation.

Strikingly, our transcriptomic results showed the upregulation of three members of the DUSP family after MPA treatment, namely DUSP1, 4 and 6, which are negative regulators of MAPK-pathways including the p38- and JNK-pathway (Table 2)64. DUSP4 and 6 have both been found to be decreased in diabetical nephropathy models65,66. If overexpressed in podocyte culture, DUSP4 decreases the activation of p38MAPK, JNK and Caspase-365. Similarly, overexpression of DUSP6 protects podocytes from synaptopodin and nephrin loss, while reducing high-glucose induced apoptosis66.

Other mentionable genes affected by MPA that could potentially play a role in the treatment of proteinuric diseases include PLK-1 and CXCL12, which were both downregulated through MPA treatment (Table 2). PLK-1 is a key regulator of the cell cycle and cell division and its inhibition has been shown to reduce proteinuria in a diabetic nephropathy model67,68. CXCL12, also known as stromal cell derived factor, is a homeostatic chemokine, whose production by podocytes has been shown to contribute to podocyte loss and albuminuria in type 2 diabetes69. Its blockage ameliorates proteinuria and increases podocyte numbers in models of both diabetical nephropathy and adriamycin-induced nephropathy70,71.

Taken together, MPA does indeed protect the actin cytoskeleton and can prevent the cell death of podocytes in cell culture. Although our results have the usual limitations of cultured podocytes regarding cell type specificity and environmental surrounding, the cell culture model is highly valuable to study effects beyond those of immune cells on podocytes, which are confounding the results in almost all in vivo models. Nevertheless, future studies will have to examine the translatability of our findings into animal models, as well as compare our findings to transcriptomic analysis of human samples. Understanding the mechanisms of action of clinically used immunosuppressive drugs in INS will help to further adapt therapeutic regimes to fully exploit its therapeutic potential. In conclusion, this study provides compelling evidence for a direct favorable effect of MPA on podocytes, while providing potential responsible pathways.

Sequencing data are available in the ArrayExpress database under the following link: https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-11702?key=76ebcb9d-12e4-4e3b-b0e2-cada7edc4bf5.

Allison, A. Mechanisms of action of mycophenolate mofetil. Lupus 14(3_Suppl), 2–8. https://doi.org/10.1191/0961203305lu2109oa (2005).

Article Google Scholar

Allison, A. C., & Eugui, E. M. Mycophenolate Mofetil and Its Mechanisms of Action. Vol 47. (2000). www.elsevier.comrlocaterimmpharm.

Eugui, E. M., Mirkovich, A. & Allison, A. C. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand. J. Immunol. 33(2), 175–183. https://doi.org/10.1111/j.1365-3083.1991.tb03747.x (1991).

Article CAS PubMed Google Scholar

Carr, S. F., Papp, E., Wu, J. C. & Natsumeda, Y. Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem. 268(36), 27286–27290. https://doi.org/10.1016/s0021-9258(19)74247-1 (1993).

Article CAS PubMed Google Scholar

Sollinger, H. Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60(3), 225–232 (1995).

Article CAS PubMed Google Scholar

Kuhn, A. et al. The diagnosis and treatment of systemic lupus erythematosus. Dtsch. Arztebl. Int. 112(25), 423–432. https://doi.org/10.3238/arztebl.2015.0423 (2015).

Article PubMed PubMed Central Google Scholar

Rovin, B. H. et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 100(4), S1–S276. https://doi.org/10.1016/j.kint.2021.05.021 (2021).

Article Google Scholar

Noone, D. G., Iijima, K. & Parekh, R. Idiopathic nephrotic syndrome in children. Lancet 392(10141), 61–74. https://doi.org/10.1016/S0140-6736(18)30536-1 (2018).

Article PubMed Google Scholar

Shalhoub, R. J. Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 304(7880), 556–560. https://doi.org/10.1016/S0140-6736(74)91880-7 (1974).

Article Google Scholar

Ravani, P. et al. Rituximab in children with steroid-dependent nephrotic syndrome: A multicenter, open-label, noninferiority, randomized controlled trial. J. Am. Soc. Nephrol. 26(9), 2259–2266. https://doi.org/10.1681/ASN.2014080799 (2015).

Article CAS PubMed PubMed Central Google Scholar

Iijima, K. et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384(9950), 1273–1281. https://doi.org/10.1016/S0140-6736(14)60541-9 (2014).

Article CAS PubMed Google Scholar

Ahn, Y. H. et al. Efficacy and safety of rituximab in childhood- onset, difficult-to-treat nephrotic syndrome. Medicine 97, 1–9 (2018).

Article Google Scholar

Tryggvason, K. & Wartiovaara, J. Molecular basis of glomerular permselectivity. Curr. Opin. Nephrol. Hypertens. 10(4), 543–549. https://doi.org/10.1097/00041552-200107000-00009 (2001).

Article CAS PubMed Google Scholar

Garg, P. A review of podocyte biology. Am. J. Nephrol. 47(suppl 1), 3–13. https://doi.org/10.1159/000481633 (2018).

Article ADS CAS PubMed Google Scholar

Benzing, T. Signaling at the slit diaphragm. J. Am. Soc. Nephrol. 15(6), 1382–1391. https://doi.org/10.1097/01.ASN.0000130167.30769.55 (2004).

Article PubMed Google Scholar

Butt, L. et al. A molecular mechanism explaining albuminuria in kidney disease. Nat. Metab. 2(5), 461–474. https://doi.org/10.1038/s42255-020-0204-y (2020).

Article CAS PubMed Google Scholar

Fornoni, A., Sageshima, J., & Wei, C., et al. Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis. (2011). www.ScienceTranslationalMedicine.org.

Hosseiniyan Khatibi, S. M., Ardalan, M., Abediazar, S. & Zununi Vahed, S. The impact of steroids on the injured podocytes in nephrotic syndrome. J. Steroid Biochem. Mol. Biol. https://doi.org/10.1016/j.jsbmb.2019.105490 (2020).

Article PubMed Google Scholar

Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 14(9), 931–938. https://doi.org/10.1038/nm.1857 (2008).

Article CAS PubMed PubMed Central Google Scholar

Ziswiler, R., Steinmann-Niggli, K., Kappeler, A., Daniel, C. & Marti, H. P. Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J. Am. Soc. Nephrol. 9(11), 2055–2066. https://doi.org/10.1681/asn.v9112055 (1998).

Article CAS PubMed Google Scholar

Hauser, I. A., Renders, L., Radeke, H. H., Sterzel, R. B. & Goppelt-Struebe, M. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol. Dial. Transplant. 14(1), 58–63. https://doi.org/10.1093/ndt/14.1.58 (1999).

Article CAS PubMed Google Scholar

Lv, W., et al. Mycophenolate Mofetil Inhibits Hypertrophy and Apoptosis of Podocyte in Vivo and in Vitro. Vol 8. www.ijcem.com/. (2015).

Nakhoul, F. et al. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: Different effects of antiproteinuric therapies. Am. J. Physiol. Ren. Physiol. https://doi.org/10.1152/ajprenal.00451.2004 (2005).

Article Google Scholar

Fu, J. et al. Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. Kidney Int. 93(2), 416–429. https://doi.org/10.1016/j.kint.2017.08.031 (2018).

Article CAS PubMed Google Scholar

Shankland, S. J., Pippin, J. W., Reiser, J. & Mundel, P. Podocytes in culture: Past, present, and future. Kidney Int. 72(1), 26–36. https://doi.org/10.1038/sj.ki.5002291 (2007).

Article CAS PubMed Google Scholar

Benz, M. R. et al. Generation and validation of a limited sampling strategy to monitor mycophenolic acid exposure in children with nephrotic syndrome. Ther. Drug Monit. 41(6), 696–702. https://doi.org/10.1097/FTD.0000000000000671 (2019).

Article CAS PubMed Google Scholar

Peifer, M. et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526(7575), 700–704. https://doi.org/10.1038/nature14980 (2015).

Article ADS CAS PubMed PubMed Central Google Scholar

George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524(7563), 47–53. https://doi.org/10.1038/nature14664 (2015).

Article ADS CAS PubMed PubMed Central Google Scholar

Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30(15), 2114–2120. https://doi.org/10.1093/bioinformatics/btu170 (2014).

Article CAS PubMed PubMed Central Google Scholar

Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29(1), 15–21. https://doi.org/10.1093/bioinformatics/bts635 (2013).

Article CAS PubMed Google Scholar

Anders, S. & Huber, W. Differential expression and sequence-specific interaction of karyopherin α with nuclear localization sequences. J. Biol. Chem. 272(7), 4310–4315. https://doi.org/10.1074/jbc.272.7.4310 (1997).

Article Google Scholar

Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15(12), 1–21. https://doi.org/10.1186/s13059-014-0550-8 (2014).

Article CAS Google Scholar

Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43(7), e47. https://doi.org/10.1093/nar/gkv007 (2015).

Article CAS PubMed PubMed Central Google Scholar

Alexa, A., & Rahnenführer, J. topGO: Enrichment analysis for Gene Ontology. R Packag version 2460. http://bioconductor.org/packages/release/bioc/html/topGO.html. (2021).

Alexa, A., Rahnenführer, J. & Lengauer, T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 22(13), 1600–1607. https://doi.org/10.1093/bioinformatics/btl140 (2006).

Article CAS PubMed Google Scholar

Kolde, R. Pheatmap: Pretty heatmaps. R Pacakage Version. ;61(926). https://cran.r-project.org/package=pheatmap (2019).

Yoshida, S., Nagase, M., Shibata, S. & Fujita, T. Podocyte injury induced by albumin overload in vivo and in vitro: Involvement of TGF-beta and p38 MAPK. Nephron Exp. Nephrol. https://doi.org/10.1159/000124236 (2008).

Article PubMed Google Scholar

Ning, L., Suleiman, H. Y. & Miner, J. H. Synaptopodin is dispensable for normal podocyte homeostasis but is protective in the context of acute podocyte injury. J. Am. Soc. Nephrol. https://doi.org/10.1681/asn.2020050572 (2020).

Article PubMed PubMed Central Google Scholar

Nolop, K. B. & Ryan, U. S. Enhancement of tumor necrosis factor-induced endothelial cell injury by cycloheximide. Am. J. Physiol. Lung Cell Mol. Physiol. https://doi.org/10.1152/ajplung.1990.259.2.l123 (1990).

Article Google Scholar

Kieckhöfer, E. et al. Primary cilia suppress Ripk3-mediated necroptosis. Cell Death Discov. 8(1), 1–12. https://doi.org/10.1038/s41420-022-01272-2 (2022).

Article CAS Google Scholar

Hoglen, N. C. et al. tetrafluoro-phenoxy ) -pentanoic Acid ): A liver-targeted caspase inhibitor. J. Cell. Mol. Med. 309(2), 634–640 (2004).

CAS Google Scholar

Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9(7), 676–682. https://doi.org/10.1038/nmeth.2019 (2012).

Article CAS PubMed Google Scholar

Nakajo, A. et al. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J. Am. Soc. Nephrol. 18(9), 2554–2564. https://doi.org/10.1681/ASN.2006070732 (2007).

Article CAS PubMed Google Scholar

Drenckhahn, D. & Franke, R. P. Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab Invest. 59(5), 673–682 (1988).

CAS PubMed Google Scholar

Greka, A. & Mundel, P. Cell biology and pathology of podocytes. Annu. Rev. Physiol. 74, 299–323. https://doi.org/10.1146/annurev-physiol-020911-153238 (2012).

Article CAS PubMed Google Scholar

Perico, L., Conti, S., Benigni, A. & Remuzzi, G. Podocyte-actin dynamics in health and disease. Nat. Rev. Nephrol. 12(11), 692–710. https://doi.org/10.1038/nrneph.2016.127 (2016).

Article CAS PubMed Google Scholar

Yu, S. M. W., Nissaisorakarn, P., Husain, I. & Jim, B. Proteinuric kidney diseases: A podocyte’s slit diaphragm and cytoskeleton approach. Front. Med. https://doi.org/10.3389/fmed.2018.00221 (2018).

Article PubMed PubMed Central Google Scholar

Asanuma, K. et al. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat. Cell Biol. 8(5), 485–491. https://doi.org/10.1038/ncb1400 (2006).

Article CAS PubMed Google Scholar

Chalovich, J. M. & Schroeter, M. M. Synaptopodin family of natively unfolded, actin binding proteins: Physical properties and potential biological functions. Biophys. Rev. 2(4), 181–189. https://doi.org/10.1007/s12551-010-0040-5 (2010).

Article CAS PubMed PubMed Central Google Scholar

Van Eldik, W. et al. Z-disc protein CHAPb induces cardiomyopathy and contractile dysfunction in the postnatal heart. PLoS ONE 12(12), 1–22. https://doi.org/10.1371/journal.pone.0189139 (2017).

Article CAS Google Scholar

Srivastava, T., Garola, R. E., Whiting, J. M. & Alon, U. S. Synaptopodin expression in idiopathic nephrotic syndrome of childhood. Kidney Int. 59(1), 118–125. https://doi.org/10.1046/j.1523-1755.2001.00472.x (2001).

Article CAS PubMed Google Scholar

Li, D., Lu, Z., Jia, J., Zheng, Z. & Lin, S. Changes in microRNAs associated with podocytic adhesion damage under mechanical stress. JRAAS J. Renin-Angiotensin-Aldosterone Syst. 14(2), 97–102. https://doi.org/10.1177/1470320312460071 (2013).

Article CAS PubMed Google Scholar

Cheng, Y. C., Chen, C. A., Chang, J. M. & Chen, H. C. Albumin overload down-regulates integrin-β1 through reactive oxygen species-endoplasmic reticulum stress pathway in podocytes. J. Biochem. 158(2), 101–108. https://doi.org/10.1093/jb/mvv020 (2014).

Article CAS Google Scholar

Dessapt, C. et al. Mechanical forces and TGFβ1 reduce podocyte adhesion through α3β1 integrin downregulation. Nephrol. Dial. Transpl. 24(9), 2645–2655. https://doi.org/10.1093/ndt/gfp204 (2009).

Article CAS Google Scholar

Lee, H. W. et al. A podocyte-based automated screening assay identifies protective small molecules. J. Am. Soc. Nephrol. 26(11), 2741–2752. https://doi.org/10.1681/ASN.2014090859 (2015).

Article CAS PubMed PubMed Central Google Scholar

Zarubin, T., Han, J. Activation and Signaling of the P38 MAP Kinase Pathway. Vol 15. www.cell-research.com7C (2005).

Xu, C. et al. Endoplasmic reticulum stress: Cell life and death decisions Find the latest version: Review series Endoplasmic reticulum stress: Cell life and death decisions. J. Clin. Invest. 115(10), 2656–2664. https://doi.org/10.1172/JCI26373.2656 (2005).

Article CAS PubMed PubMed Central Google Scholar

Gonçalves, G. L., Costa-Pessoa, J. M., Thieme, K., Lins, B. B. & Oliveira-Souza, M. Intracellular albumin overload elicits endoplasmic reticulum stress and PKC-delta/p38 MAPK pathway activation to induce podocyte apoptosis. Sci. Rep. https://doi.org/10.1038/s41598-018-36933-9 (2018).

Article PubMed PubMed Central Google Scholar

Koshikawa, M. et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J. Am. Soc. Nephrol. 16(9), 2690–2701. https://doi.org/10.1681/ASN.2004121084 (2005).

Article CAS PubMed Google Scholar

Pengal, R. et al. Inhibition of the protein kinase MK-2 protects podocytes from nephrotic syndrome-related injury. Am. J. Physiol. Ren. Physiol. 301, 509–519. https://doi.org/10.1152/ajprenal.00661.2010.-While (2011).

Article Google Scholar

Okamura, K. et al. Endocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death. PLoS One https://doi.org/10.1371/journal.pone.0054817 (2013).

Article PubMed PubMed Central Google Scholar

Pedigo, C. E. et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J. Clin. Invest. 126(9), 3336–3350. https://doi.org/10.1172/JCI85939 (2016).

Article PubMed PubMed Central Google Scholar

Chen, A. et al. Soluble RARRES1 induces podocyte apoptosis to promote glomerular disease progression. J. Clin. Invest. 130(10), 5523–5535. https://doi.org/10.1172/JCI140155 (2020).

Article CAS PubMed PubMed Central Google Scholar

Huang, C. Y. & Tan, T. H. DUSPs, to MAP kinases and beyond. Cell Biosci. https://doi.org/10.1186/2045-3701-2-24 (2012).

Article PubMed PubMed Central Google Scholar

Denhez, B. et al. Diabetes-induced DUSP4 reduction promotes podocyte dysfunction and progression of diabetic nephropathy. Diabetes 68(5), 1026–1039. https://doi.org/10.2337/db18-0837 (2019).

Article CAS PubMed Google Scholar

Chen, L. et al. DUSP6 protects murine podocytes from high glucose-induced inflammation and apoptosis. Mol. Med. Rep. 22(3), 2273–2282. https://doi.org/10.3892/mmr.2020.11317 (2020).

Article CAS PubMed PubMed Central Google Scholar

Barr, F. A., Silljé, H. H. W. & Nigg, E. A. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 5(6), 429–440. https://doi.org/10.1038/nrm1401 (2004).

Article CAS PubMed Google Scholar

Zhang, L. et al. Connectivity mapping identifies BI-2536 as a potential drug to treat diabetic kidney disease. Diabetes 70(2), 589–602. https://doi.org/10.2337/db20-0580 (2021).

Article CAS PubMed Google Scholar

Sayyed, S. G. et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52(11), 2445–2454. https://doi.org/10.1007/s00125-009-1493-6 (2009).

Article CAS PubMed Google Scholar

Darisipudi, M. N. et al. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am. J. Pathol. 179(1), 116–124. https://doi.org/10.1016/j.ajpath.2011.03.004 (2011).

Article CAS PubMed PubMed Central Google Scholar

Romoli, S. et al. CXCL12 blockade preferentially regenerates lost podocytes in cortical nephrons by targeting an intrinsic podocyte-progenitor feedback mechanism. Kidney Int. 94(6), 1111–1126. https://doi.org/10.1016/j.kint.2018.08.013 (2018).

Article CAS PubMed PubMed Central Google Scholar

Download references

Open Access funding enabled and organized by Projekt DEAL. A.H. is a holder of a GPN (German Society for Pediatric Nephrology) grant and a stipend from Peter Stiftung. A.H. and S.AZ. were funded by Cologne Fortune stipend. We acknowledge support for the Article Processing Charge from the DFG (German Research Foundation, 491454339)

These authors contributed equally: Seif El Din Abo Zed and Agnes Hackl.

Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, University of Cologne, Cologne, Germany

Seif El Din Abo Zed, Agnes Hackl, Gregor Fink, Kai-Dietrich Nüsken, Eva Nüsken & Lutz T. Weber

Faculty of Medicine and University Hospital Cologne, Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany

Seif El Din Abo Zed, Agnes Hackl, Katrin Bohl, Lena Ebert, Emilia Kieckhöfer, Roman-Ulrich Müller & Bernhard Schermer

Faculty of Medicine and University Hospital Cologne, Pharmacology at the Laboratory Center, Department of Therapeutic Drug Monitoring DE, University of Cologne, Cologne, Germany

Carsten Müller

Faculty of Medicine and University Hospital Cologne, Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany

Kerstin Becker

Cologne Cluster of Excellence on Cellular Stress Responses in Ageing-Associated Diseases (CECAD), University of Cologne, Cologne, Germany

Katrin Bohl, Lena Ebert, Emilia Kieckhöfer, Roman-Ulrich Müller & Bernhard Schermer

Faculty of Medicine and University Hospital Cologne, Center for Rare Kidney Diseases Cologne, University of Cologne, Cologne, Germany

Roman-Ulrich Müller

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

A.H., K.-D.N., E.N., C.M., B.S. and L.T.W. conceptualized and developed the methodology of the present work. S.AZ., A.H., L.E., E.K. and G.F. investigated the present matter and performed the experiments and data collection. K.B. and K.B. formally analyzed the data. S.AZ. and A.H. wrote the article. A.H. K.-D.N., E.N. R.-U.M. and L.T.W. reviewed and edited the article. L.T.W., B.S., K.-D.N. and R.-U.M. administered the project and provided supervision and oversight. All authors reviewed the manuscript.

Correspondence to Agnes Hackl.

The authors declare no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

Abo Zed, S.E.D., Hackl, A., Bohl, K. et al. Mycophenolic acid directly protects podocytes by preserving the actin cytoskeleton and increasing cell survival. Sci Rep 13, 4281 (2023). https://doi.org/10.1038/s41598-023-31326-z

Download citation

Received: 21 October 2022

Accepted: 09 March 2023

Published: 15 March 2023

DOI: https://doi.org/10.1038/s41598-023-31326-z

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.